Oxford Cannabinoid's breakthrough oral immunotherapy: “The initial data demonstrates excellent potential”
Episode 1542, Jul 17, 2023, 02:05 PM
(Watch the video interview HERE)
In this video, Vox Markets talks to Clarissa Sowemimo-Coker, CEO of
Oxford Cannabinoid (OCTP), a biotech company focused on developing prescription medications from cannabinoids, taking Vox through the company's mission to address unmet patient needs, particularly within the US multi-billion dollar pain market. They announce their expansion into oncology and the potential of a first-in-class oral immunotherapy for solid tumors.
In this video, Vox Markets talks to Clarissa Sowemimo-Coker, CEO of
Oxford Cannabinoid (OCTP), a biotech company focused on developing prescription medications from cannabinoids, taking Vox through the company's mission to address unmet patient needs, particularly within the US multi-billion dollar pain market. They announce their expansion into oncology and the potential of a first-in-class oral immunotherapy for solid tumors.